Treatment of Superior Mesenteric Vein Thrombus by Catheter-Directed Thrombolysis

Ann Vasc Surg. 2020 May:65:286.e9-286.e13. doi: 10.1016/j.avsg.2019.11.021. Epub 2019 Nov 16.

Abstract

Contrast-enhanced computed tomography (CT) greatly improves the diagnosis of superior mesenteric vein (SMV) thrombosis, which presents as the unspecific symptom of abdominal pain. Prothrombotic states or thrombophilia and local intra-abdominal infections are major causes of SMV thrombosis. A 37-year-old Chinese woman was diagnosed with SMV and portal vein thrombosis. The patient was initially given 40 mg of heparin sodium every 12 hr and 80,0000 U/day of urokinase using superior mesenteric artery angiography. The abdominal pain was not relieved after treatment. The patient then underwent open surgery, where an ileal branch of the SMV was punctured, a 4F sheath was introduced into the vein toward the portal vein, and a 20-cm Unifuse catheter was placed inside the thrombus for further thrombolysis. Both heparin sodium and urokinase were infused through catheter-directed thrombolysis. The patient's symptoms then gradually resolved.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Female
  • Fibrinolytic Agents / administration & dosage*
  • Humans
  • Mesenteric Ischemia / diagnostic imaging
  • Mesenteric Ischemia / drug therapy*
  • Mesenteric Ischemia / physiopathology
  • Mesenteric Vascular Occlusion / diagnostic imaging
  • Mesenteric Vascular Occlusion / drug therapy*
  • Mesenteric Vascular Occlusion / physiopathology
  • Mesenteric Veins* / diagnostic imaging
  • Mesenteric Veins* / physiopathology
  • Thrombolytic Therapy*
  • Treatment Outcome
  • Urokinase-Type Plasminogen Activator / administration & dosage*
  • Venous Thrombosis / diagnostic imaging
  • Venous Thrombosis / drug therapy*
  • Venous Thrombosis / physiopathology

Substances

  • Fibrinolytic Agents
  • Urokinase-Type Plasminogen Activator